San Diego-based Fate Therapeutics Enters Strategic Collaboration with Tokyo’s ONO Pharmaceutical Co.

San Diego-based Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.  For more information, please visit www.fatetherapeutics.com.

 

 

 

Fate’s proprietary iPSC product platform is reported to enable mass production of off-the-shelf, engineered, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be reproducibly produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf to treat many patients. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 100 issued patents and 100 pending patent applications.

On Monday, September 17th, Fate Therapeutics, Inc. announced that it has entered into a collaboration with Tokyo-based ONO Pharmaceutical Co., Ltd. (approximately 300-year-old organization) for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics will receive an upfront payment and committed research funding during the preclinical option period, and is eligible to receive a preclinical option exercise fee, clinical, regulatory and commercialization milestone payments and tiered royalties on net sales by ONO in connection with the development and commercialization of each collaboration product by ONO in the ONO territory.

 

 

 

Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. This transformative approach enables the cost-effective production of cell-based cancer immunotherapies that are uniformly engineered, extensively characterized and homogeneous in composition, and can be consistently and repeatedly mass produced and delivered to patients in an off-the-shelf manner.

Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are delighted to collaborate with ONO, a global leader in oncology with a long history of developing innovative breakthrough cancer drugs. This partnership with ONO enables Fate to further enhance its expertise in targeting solid tumors and to accelerate the global development of our pipeline of off-the-shelf, iPSC-derived CAR-T cell product candidates.”

Under the terms of the strategic option agreement, Fate Therapeutics and ONO will jointly advance each iPSC-derived CAR-T cell collaboration candidate to a pre-defined preclinical milestone.

  • The first iPSC-derived CAR T-cell candidate targets an antigen expressed on certain lymphoblastic leukemias, and Fate Therapeutics retains global responsibility for development and commercialization with ONO having an option to assume responsibilities in Asia.
  • The second candidate targets a novel antigen identified by ONO expressed on certain solid tumors, with ONO having an option to assume global responsibility for further development and commercialization and Fate Therapeutics retaining the right to co-develop and co-commercialize the candidate in the United States and Europe. For both collaboration candidates, Fate Therapeutics retains manufacturing responsibilities on a global basis.

Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of ONO stated, “ONO identified Fate Therapeutics as the partner of choice for the generation of off-the-shelf CAR T-cell cancer immunotherapies in our portfolio. We are excited to work with Fate Therapeutics and apply its industry-leading iPSC product platform to develop and deliver the next-generation of CAR T-cell therapies for cancer patients.”

If you found this story interesting you should consider reading about Seattle-based Atossa Genetics (Nasdaq: ATOS) which is is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. To learn more please see the  dedicated coverage page at Vista Partners.

Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization..

finance.yahoo.com

Read Full Article



The Ocean Cleanup Makes Start in San Francisco Bay…Aiming Toward Great Pacific Garbage Patch

The nonprofit Ocean Cleanup, whose mission is to develop “advanced technologies to rid the world’s oceans of plastic,” sent out its floating boom system from the San Francisco Bay on Saturday. The system, which was founded by Dutch inventor, Boyan Slat, is on a mission to clean up the nearly 1.8 trillion pieces of floating trash in the Great Pacific Garbage Patch.

The floating boom system, along with dozens of other booms, is expected to take 5 years to clean up half the trash in the Great Pacific Garbage Patch. Each of the booms has the ability to collect up to 150,000 pounds of plastic per year.

What is the Great Pacific Garbage Patch you ask? It is a vortex of trash that lies halfway between California and Hawaii that was created from an ocean gyre in the central North Pacific. The patch is so massive that is can be detected from space and covers 1.6 million square kilometers! Yikes….

The boom system will be towed out to the garbage patch in mid-October to begin its trash trapping. The floating boom drifts in conjunction with the local currents create a U-shaped formation. As it floats along, trash is collected in the U-shaped system that has 10 feet of netting below it to collect the smaller fragments of plastic. When the boom becomes full, a vessel meets the boom to collect the plastic and transport it back to land so that it can be sorted and recycled or reused.

Although the technology has got to prove itself in the open ocean, it would seem to be the closest solution to cleaning up the enormous garbage patch.

We are wishing it the best of luck and great success!

Free stock photo of sea, city, landscape, sky

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

The World’s Largest Ocean Cleanup Has Officially Begun

..

www-forbes-com.cdn.ampproject.org

Read Full Article



First Choice Bancorp (FCBP) Appointed Lynn M. Hopkins As Executive Vice President & Chief Financial Officer

First Choice Bancorp is a community-based bank holding company headquartered in Cerritos, California, and it is the sole shareholder of First Choice Bank.

First Choice Bancorp (Nasdaq: FCBP) recently announced that Lynn M. Hopkins has been appointed Executive Vice President and Chief Financial Officer, effective September 13, 2018. Ms. Hopkins succeeds Yvonne Chen, who will now serve as the Company’s Executive Vice President of Finance, overseeing financial planning and analysis. Ms. Hopkins has more than 25 years of experience in the financial services industry including 15 years in executive finance positions at PacWest Bancorp. Ms. Hopkins joins First Choice most recently from Commercial Bank of California, an $800 million private commercial bank, where she served as Executive Vice President & Chief Financial Officer. From 2002 to 2017, Ms. Hopkins served as Executive Vice President of PacWest Bancorp and Pacific Western Bank, the subsidiary bank of PacWest Bancorp, in a number of finance and corporate governance leadership roles. Ms. Hopkins served as Chief Accounting Officer of PacWest from 2014 to 2017, as Chief Financial Officer of Pacific Western Bank from 2002 to 2014, as Corporate Secretary from 2009 to 2014, and as a Director of the Pacific Western Bank from 2002 to 2006. During her time at PacWest, the company grew from $1 billion in assets to more than $20 billion in assets, partially driven by more than 25 acquisitions. Earlier in her career, Ms. Hopkins held senior finance positions at California Community Bancshares and Western Bancorp. She began her career as a CPA with KPMG in Los Angeles and London. Ms. Hopkins holds a B.A. in Economics/Business from the University of California, Los Angeles.

Robert Franko, President and Chief Executive Officer of First Choice stated, “We are very pleased to add an executive of Lynn’s caliber to lead our finance department. Lynn’s experience in financial reporting for a public company and her risk management experience in helping to manage the organic and acquisitive growth at PacWest will be valuable as we integrate our recent acquisition of Pacific Commerce Bancorp and continue expanding our franchise. Her well-rounded skill set and leadership abilities are well suited to handle the increased responsibilities for our finance department following our NASDAQ listing and transformative merger with Pacific Commerce. We would also like to recognize Yvonne Chen for her valuable service as Chief Financial Officer for more than a decade. Yvonne was instrumental in leading us to become a public company while initiating and completing the merger with Pacific Commerce. We are very pleased that she will remain at First Choice in her chosen role as the Executive Vice President of Finance so that we can continue to benefit from her expertise and institutional knowledge,” added Mr. Franko.

Peter Hui, Chairman of First Choice, stated, “We are very proud to be able to welcome a professional like Lynn to our team. In addition, we recognize the valuable service that Yvonne has provided to First Choice.

Ms. Hopkins stated, “I am excited to join a growing organization that has achieved several milestones in a short period of time. I look forward to making a meaningful contribution to the future growth and success of First Choice.”

First Choice Bancorp is a community-based bank holding company headquartered in Cerritos, California, and it is the sole shareholder of First Choice Bank. As of July 31, 2018, First Choice had total assets of approximately $1.5 billion. First Choice Bank is a community-focused financial institution, serving diverse consumers and commercial clients and specializing in loans to small businesses, private banking clients, commercial and industrial (C&I) loans, and commercial real estate loans with a niche in providing financing for the hospitality industry. First Choice Bank is a Preferred Small Business Administration (SBA) Lender. Founded in 2005, First Choice Bank has quickly become a leading provider of financial services that enable our customers to grow, maintain strength, and achieve their business objectives. We strive to surpass our clients’ expectations through our efficiency and professionalism and are committed to being “First in Speed, Service, and Solutions.” First Choice Bancorp stock is traded on the Nasdaq Capital Market under the ticker symbol “FCBP.”

Lynn M. Hopkins Named Chief Financial Officer of First Choice Bancorp

First Choice Bancorp (FCBP) (“First Choice” or the “Company”) today announced that Lynn M. Hopkins has been appointed Executive Vice President and Chief Financial Officer, effective September 13, 2018. Ms. Hopkins succeeds Yvonne Chen, who will now serve as the Company’s Executive Vice President of..

finance.yahoo.com

Read Full Article



Have You Read “Vista Partners Weekly Market Update 9-15-18?”

Vista Partners published “Vista Partners Weekly Market Update 9-15-18!” 

Each weekly issue is written by Vista Partners’ Managing Director, John Heerdink!

Each weekly issue includes updates on the stock market, a “Stocks To Watch” section, & featured daily stories & videos from Vista’s Coverage Universe of Dow 30 components, International and Select Emerging Growth Companies & more.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page now.

Stay Informed! Stay Competitive!  Receive our FREE updates by signing up today!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Will You Be One Of The First To Get Apple’s New iPhone Xs?

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it.”

Apple revealed its new line of iPhones this week, a highly anticipated moments for both its consumers and investors. The flagship model of this line the iPhone Xs, which will be available in stores September 21, will cost $999. Also available September 21, the larger model, the Xs Max will cost $1,099 and the “budget” model will sell for $749.

Will you be one of the first to get one?… I will be waiting but I am always amazed at how many are willing to stand in line to be the first.

The new iPhone Xs, which is the same size as the current iPhone X, will be very similar to the iPhone X but will boast a faster processor, more dynamic display, and an upgraded camera. The new model will be available in gold, silver, and space gray.

The larger model, the iPhone Xs Max will be released as the largest iPhone ever with a screen of 6.5 inch. Both Xs models will be more splash and water-resistant with the ability to withstand up to six and a half feet of water for 30 minutes. The new line will also debut with features like better speakers, faster FaceID, improved display, and cameras that have new, larger sensors, bigger pixels, and faster processors.

“A12 Bionic” is the new processor for the phone line that will boost speed to 5 trillion operations per second. Along with all the new hardware updates, the new iOS, 12, promises to be nine times faster and use only a tenth of the energy.

The new iPhone Xs battery life adds an extra 30 minutes to the X and the Xs Max adds 90 minutes to the battery life.

iPhone Xr, the budget model, uses aluminum instead of steel and features a 6.1-inch LCD screen instead of an OLED screen which is more expensive and is what is used on the higher end iPhone models.

Learn more about Apple and track its ongoing progress at Vista Partners Apple (AAPL) Coverage Page.

Woman Wearing Green Sunglasses

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Apple unveils new flagship phone for $1099 and ‘budget’ model for $749

Apple releases new iPhone models at its 2018 event…

finance.yahoo.com

Read Full Article



Chevron & Others Demand Hearing with FERC on Colonial Rates

U.S. regulators have been begged to expedite a hearing on the fee structure of Colonial Pipeline Co, the largest fuel pipeline in the United States. The complaint was filed by Chevron Corp, Valero Energy Corp, and Delta Air Lines Inc, claiming that the fee structure of Colonial costs them millions of dollars. The complaint also cites that Colonial has overcharged the companies by over $60 million combined over a two-year period, and accuses Colonial of likely monopolizing the fuel delivery into the New York region.

The three companies have stated that the lack of a scheduled hearing by the U.S. Federal Energy Regulatory Commission (FERC) is currently costing them almost $4.95 million a month. The complaint has been pending with FERC for nine months.

Colonial, which has over 5,500 miles of pipeline system that connects the Gulf Coast refineries to markets in the southern and eastern U.S., says that the complaint has no merit and that the data the companies used has been manipulated to strengthen their argument.

Tamara Young-Allen, the FERCA spokeswoman, declined to comment on the filed complaint, stating that it is policy to make no comment on a pending Commission decision.

More information on the filed complaint can be found here.

To learn more about Chevron (CVX) and to track their progress please visit the Vista Partners Chevron Page.

Black And White Cat

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Walgreens Positioning to Acquire Pharmacy Patient Prescription Files & Inventory of Fred’s Pharmacies In Southeast

Walgreen Boots Alliance (WBA), a recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates.

Walgreens is reportedly now in a position to acquire the pharmacy patient prescription files and the related pharmacy inventory of 185 Fred’s stores across the Southeastern states in a definitive asset purchase agreement. In the current agreement, Walgreens will pay $165 million along with an amount that is equal to the value of the related pharmacy inventory.

Expected to be completed in the first quarter of calendar 2019, the deal comes a part of Fred’s earlier announced plan to unlock shareholder value by monetizing non-core assets through strategic transactions.

A letter will be sent to those patients whose prescriptions are being transferred. Upon completion of the transfer, the patients will have access to Walgreens pharmacy services across the company almost 9,800 pharmacies across the nation.

Richard Ashworth, Walgreens President of Operations stated, “This agreement increases patient access to Walgreens pharmacies in the Southeastern U.S., and allows us to introduce more people to Walgreens trusted pharmacy services in these communities. We look forward to welcoming Fred’s patients and team members who are hired into available Walgreens positions.

To learn more about Walgreen Boots Alliance (WBA) and to continue to track its progress please visit the Vista Partners Walgreens Boots Alliance Page.

Woman Holding Bouquet of Flowers

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Walgreens to Purchase Pharmacy Files of 185 Fred’s Pharmacies Across Southeastern U.S.

Walgreens and Fred’s, Inc. (FRED) today announced they have entered into a definitive asset purchase agreement, pursuant to which Walgreens will acquire pharmacy patient prescription files and related pharmacy inventory of 185 Fred’s stores located across 10 Southeastern states. Under the agreement..

finance.yahoo.com

Read Full Article



Dow 30 Component Boeing Hires Retirees in Effort to Catch 737 Production Lags In Seattle

Dow 30 component Boeing (NYSE: BA)  is the world’s largest aerospace company and leading manufacturer of commercial jetliners and defense, space and security systems.  A top U.S. exporter, the company supports airlines and U.S. and allied government customers in 150 countries. Boeing products and tailored services include commercial and military aircraft, satellites, weapons, electronic and defense systems, launch systems, advanced information and communication systems, and performance-based logistics and training.

In an effort to fix delays at its 737 jetliner plant outside of Seattle, Washington, the Boeing Co is bringing in retired workers. The hiccup was caused by a shortage of engines and fuselages as the company sped up production to record levels this past June. This snag could hurt third-quarter results and threaten Boeing’s goal to increase its build rates in the 2019 year.

Aircrafts with single-aisles like the popular 737 are the moneymakers for the two largest aircraft manufacturers in the world.

Boeing began the temporary hiring of the retire mechanics and inspectors after the company reached an agreement with the International Association of Machinists and Aerospace Workers on August 15. Last fall, Boeing formed another similar agreement with the union after a round of voluntary layoffs.

The company has already sent nearly 600 employees and new hires to the Washington location in the past few weeks to assist with fixing the delays. Boeing has not stated how many retired workers they intend to hire.

Paul Bergman, Boeing spokesman stated, “We are working closely with our suppliers Spirit and CFM as they track toward recovery, as well as our customers. Our team has been mitigating supplier delays, and our factory continues to build 52 airplanes per month.”

To learn more about Boeing (BA) and to track its ongoing progress please visit the Vista Partners Boeing (BA) Coverage Page.

Photography of a Woman Sitting on Chair

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Boeing calling back retirees to fix 737 production snags

Boeing Co is bringing retired workers back on the job as the world’s largest planemaker tries to fix delays at its 737 jetliner plant outside Seattle, a union official told Reuters on Monday. The snarl at its plant in Renton, Washington, triggered by shortages of engines and fuselages as Boeing..

finance.yahoo.com

Read Full Article



Atossa Advancing Into Phase 2 Study to Reduce Gynecomastia In Men Starting Prostate Cancer Therapy

Gynecomastia is male breast enlargement and accompanying pain, which according to the Mayo Clinic, affects 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone levels are lower than estrogen. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer, anti-anxiety medications, cancer treatments (chemotherapy), and some heart medications.

Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking their prescribed medication. In prostate cancer treatment, testosterone is suppressed resulting in higher estrogen levels that often triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).

There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the use of daily oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated. Gynecomastia can create quality of life issues, with some patients attempting to hide the condition with compression garments and, in some cases, undergoing plastic surgery.

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported earlier today their preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. All objectives were announced to have been successfully met as follows:

  • Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen.
  • Tolerability: Topical Endoxifen was well tolerated at each dose level and for the dosing duration utilized in the study.
  • Pharmacokinetics: Blood samples showed no measurable topical Endoxifen.

 

 

 

 

 

Dr. Steven C. Quay, CEO, and President of Atossa stated, “Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy. We anticipate retaining a clinical research organization to manage that study in the fourth quarter of 2018. In addition to advancing our mens’ program into a Phase 2 study, we also have multiple Phase 2 studies in women addressing large markets with significant unmet needs: breast cancer and a condition called mammographic breast density. We look forward to reporting progress on these programs in the fourth quarter of 2018 and into 2019.”

 

 

 

 

 

Conference Call

Atossa Genetics hosted a conference call to discuss preliminary results today at 10 am Eastern time. A replay of the call will be available approximately one hour after the end of the call through October 13, 2018. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll-Free at 855-669-9658. The replay access code is 10124008.

 

 

 

 

 

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects…

finance.yahoo.com

Read Full Article



Wells Fargo Claims Amazon Will Be Crowned No. 1 Retailer of Apparel In US in 2018

Amazon.com, the world’s largest retailer,  will take Walmart’s place at the top as it takes the clear title of No. 1 seller of apparel in the U.S. for 2018 according to Wells Fargo. Wells Fargo also expects Amazon’s apparel and footwear gross sales to reach over $30 billion this year.

The e-commerce giant has seen its shares rally over 22 percent in that last six months and 100 percent in the past year under the leadership of chief executive Jeff Bezos. The company even topped $1 trillion in market value for a brief bit.

Woman Holding Man's Hand During Day

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Amazon will dethrone Walmart as the No. 1 retailer of apparel this year, predicts Wells Fargo

Amazon will be the No. 1 seller of apparel in the U.S. in 2018, according to Wells Fargo, which raised its price target on the Seattle-based retailer Monday following new analysis into its clothing segment…

www.cnbc.com

Read Full Article